Keeping you on anifrolumab after a positive finish with your prior study

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 3 rollover study designed to provide continued access to anifrolumab for participants who completed a parent trial and benefited from the treatment. Eligible participants may enroll if they received at least one dose in the prior study and there was ongoing clinical benefit. Safety and tolerability will be monitored as dosing continues in the same manner as in the parent study. Enrollment can begin after the parent study’s final safety follow-up visit is completed. The study is conducted at selected sites in Arizona and California under AstraZeneca sponsorship.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants are eligible to be included in the study only if all of the following criteria apply:

  1 Participants must have completed the entirety of the parent study and should have received at least one dose of anifrolumab in the parent study.
* In the opinion of the Investigator, the potential benefit to the participant of continuing anifrolumab at the end of the parent study outweighs the risk.
* Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Participants should continue following the contraception requirements as per Appendix B from study enrolment up to 16 weeks after the last dose of study treatment.
* Capable of giving signed informed consent described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
* Capable of adhering to the treatment plan related to this ROSY-S study.

Exclusion Criteria:

* Participant develops hypersensitivity to any of the components of anifrolumab.
* Female participant who is breastfeeding, pregnant, or intends to become pregnant during participation in this study.
* Currently participating in any investigational study or participated in an investigational study within 30 days prior to enrolment or within 5 half-lives of the investigational medicinal product (other than the parent study for anifrolumab) whichever is longer.
* Ongoing, unresolved AE requiring interruption of treatment at the end of the prior parent study (ie, when the parent study is either completed or closed) that in the Investigator's opinion would prevent restarting anifrolumab.
* Currently receiving or have received prohibited medication(s) as specified in parent protocols prior to signing ICF.
* Participants who are planning to use live/live-attenuated vaccines.
* Participants who are planning to use any other therapies, including B-cell therapies, that in the opinion of the Investigator could jeopardize or would compromise the participant's ability to participate in the program as determined by the Investigator.
* Participants with any medical condition (such as cancer or viral infections \[hepatitis\]) or psychiatric condition that, in the opinion of the Investigator, could jeopardise or would compromise the participant's ability to participate in this study as determined by the Investigator based on protocol required assessments.
* Participants who discontinued the parent study prior to completion of all study visits.
* Local access to approved and commercially available (reimbursed) drug for the defined indication as permitted by local/country regulation.

Where it's running

• Research Site
  Los Angeles, California, United States Recruiting
• Research Site
  Boca Raton, Florida, United States Recruiting
• Research Site
  Fort Lauderdale, Florida, United States Recruiting
• Research Site
  Charlotte, North Carolina, United States Recruiting
• Research Site
  Phoenix, Arizona, United States Not yet recruiting
• Research Site
  Irvine, California, United States Not yet recruiting

+116 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: +1877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effects of anifrolumab on arterial inflammation in SLE patients

  This study tests whether anifrolumab can reduce blood vessel inflammation in people with active systemic lupus erythematosus.

  Recruiting University of Cambridge · Cambridge, Cambridgeshire · NCT07913919

• Anifrolumab in Chinese patients with active moderate-to-severe SLE

  This study tests whether adding anifrolumab to standard care helps Chinese adults with active moderate-to-severe SLE achieve remission and reduces glucocorticoid use.

  Recruiting at 25 sites Phase 3 AstraZeneca · Beijing and 73 other locations · NCT07751848

• Subcutaneous anifrolumab in children with systemic lupus erythematosus

  This study tests whether subcutaneous anifrolumab is safe and how it behaves in the body for kids with moderate to severe SLE already on standard care.

  Recruiting at 2 sites Phase 2 AstraZeneca · Nedlands and 38 other locations · NCT07630714

• LUPKYNIS in combination with belimumab, obinutuzumab, or anifrolumab for lupus nephritis

  This trial tests whether adding LUPKYNIS to other biologics (belimumab, obinutuzumab, or anifrolumab) plus a mycophenolic acid analog and a steroid can rapidly improve kidney health in adults with biopsy-proven lupus nephritis.

  Recruiting at 27 sites Phase 4 Aurinia Pharmaceuticals Inc. · La Mesa, California and 26 other locations · NCT07611214

• Anifrolumab for adults with primary antiphospholipid syndrome

  This phase II pilot tests whether weekly subcutaneous anifrolumab is safe and tolerable in adults with primary antiphospholipid syndrome while they continue their standard care.

  Recruiting Phase 2 National and Kapodistrian University of Athens · Athens, Greece · NCT07584083

• Weekly subcutaneous anifrolumab added to antimalarial for people with lupus who are immunosuppressant- and biologic-naïve

  This trial tests whether once-weekly 120 mg subcutaneous anifrolumab plus antimalarial (with or without steroids) helps adults with lupus who have not used immunosuppressants or biologics reach remission and come off long-term steroids.

  Recruiting at 50 sites Phase 3 AstraZeneca · Anniston, Alabama and 107 other locations · NCT07430306

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.